Nautilus Biotechnolgy, Inc. (NASDAQ: NAUT) is a Healthcare company (Biotechnology) with a market capitalization of $301M. The Maz Rating grades it against the other companies in its sector.
Nautilus Biotechnolgy, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.36, Nautilus Biotechnolgy, Inc. trades at 715.0x sales and 2.6x book value. Over the last twelve months it generated about $420437 of revenue and a net loss of $58M. It runs a gross margin of -362.5%, an operating margin of -15105.7% and a net margin of -13816.7%. It shows return on equity of -42.7%, return on invested capital of -44.7% and a free cash flow yield of -18.3%. On the balance sheet: a debt-to-equity ratio of 0.23 and a current ratio of 9.25. Over the past 52 weeks the share price ranged from $0.84 to $4.31, with a beta of 0.87.
Nautilus Biotechnolgy, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 3 Buy, 1 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Nautilus Biotechnolgy, Inc. (NAUT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 53.6% / 30% · Interest income / Revenue 501.3% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 40.6% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 501.3% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 40.6% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 501.3% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 54.3% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 501.3% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 58.1% / 33.33% · (Cash+Recv) / Total Assets 58.1% / 33.33% · Interest income / Revenue 501.3% / 5% | Fail |
No. As of September 2026, Nautilus Biotechnolgy, Inc. (NAUT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Nautilus Biotechnolgy, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 501.3% of each dividend: Nautilus Biotechnolgy, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.